Clinical trials overview
NVG-291 is a first-in-class drug candidate currently in a Phase 1 clinical trial in healthy volunteers to evaluate safety, tolerability and metabolism. After completing our Phase 1 clinical trial, we plan to initiate Phase 1b/2 clinical trials in Alzheimer’s and spinal cord injury in 2022 and a Phase 2 in multiple sclerosis in 2023.